What is the Short Interest on Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Stock?

Mae Love
January 13, 2018

After $0.27 actual EPS reported by Sucampo Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 25.93% EPS growth. SCMP was included in 3 notes of analysts from September 7, 2016. The 52-Week High range of the stock is $27.71, while the 52-week low range is $14.54. ValuEngine raised Sucampo Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Sunday, December 31st. With 754,100 avg volume, 6 days are for Sucampo Pharmaceuticals Class A (NASDAQ:SCMP)'s short sellers to cover SCMP's short positions. Maxim Group cut shares of Sucampo Pharmaceuticals to a hold rating in a research note on Monday, January 1st. Finally, B. Riley assumed coverage on shares of Sucampo Pharmaceuticals in a research note on Tuesday, November 14th.

The company shows its Return on Assets (ROA) value of -33.5%. Six analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $21.58. Sucampo Pharmaceuticals, Inc. (SCMP)'s value Change from Open was at 1.94% with a Gap of 0.00%. The volume of 1.99 Million shares climbed down over an trading activity of 2.22 Million shares. The stock has a market capitalization of $853.46, a PE ratio of -5.49, a P/E/G ratio of 5.07 and a beta of 1.45. At the same time as, it has debt to equity ratio of 0.00 and similar long term debt to equity ratio was 7.37.

ILLEGAL ACTIVITY WARNING: "Leerink Swann Reaffirms "Market Perform" Rating for Sucampo Pharmaceuticals (NASDAQ:SCMP)" was first published by Week Herald and is the sole property of of Week Herald.

For the ongoing Fiscal Quarter, 6 analysts have an average earnings forecast of $0.22 per share. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The firm had revenue of $57.90 million for the quarter, compared to analysts' expectations of $51.30 million. According to their observations and findings, the stock could provide a high EPS of $0.38/share and a low EPS of $0.32/share.

Hollywood stars branded 'hypocrites' for Golden Globes black dress protest
We break down what's behind the polar temperatures that gripped the east coast over the weekend and the upcoming warm-up. In fact, President Trump himself mentioned her as a potential running mate when he mulled a bid in 1999.

(NYSE:DAL) EVP Sells $50511.00 in Stock
Bluemountain Management Llc has invested 0.04% of its portfolio in Delta Air Lines, Inc . (NYSE:DAL)'s Price Change % is -0.25%. Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 1.83, and a price to sales ratio of 1.4.

Here's How Some Places Trump Called "Shitholes" Are Reacting To His Comments
Trump did not respond to shouted questions about his comments as he signed a proclamation Friday honoring Martin Luther King Jr. Commenting on the White House meeting, Graham said on Friday that diversity had always been the United States' strength.

In other news, insider Peter A. Kiener sold 50,000 shares of Sucampo Pharmaceuticals stock in a transaction that occurred on Thursday, December 7th. Dimensional Fund Advisors LP now owns 1,570,172 shares of the biopharmaceutical company's stock valued at $16,487,000 after buying an additional 15,528 shares in the last quarter. Following the transaction, the insider now owns 52,023 shares in the company, valued at $858,379.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Several hedge funds have recently bought and sold shares of the company. Nine Chapters Capital Management LLC purchased a new position in Sucampo Pharmaceuticals in the 3rd quarter worth about $127,000. As reported by Linden Capital L.P., the filler owns 4.6% or 2,264,288 shares of the Health Care-company. Rhumbline Advisers raised its holdings in shares of Sucampo Pharmaceuticals by 0.9% in the second quarter. Last quarter, the company saw 61.27 million in total revenues.

What to Expect From Sucampo Pharmaceuticals, Inc. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company's stock valued at $126,000 after buying an additional 631 shares during the period. It also upped Qualcomm Inc (Call) (NASDAQ:QCOM) stake by 1.81 million shares and now owns 6.29M shares. Vanguard Group Inc. increased its position in Sucampo Pharmaceuticals by 13.0% during the 2nd quarter. Thrivent Financial For Lutherans now owns 15,270 shares of the biopharmaceutical company's stock valued at $160,000 after purchasing an additional 1,550 shares during the last quarter. However, the institutional investors are observed to own 98.40% of the total shares. If you are reading this report on another publication, it was illegally copied and reposted in violation of global trademark and copyright law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/12/sucampo-pharmaceuticals-scmp-given-neutral-rating-at-mizuho.html. This continues to be an interesting story, and we look forward to updating it again soon on Sucampo Pharmaceuticals, Inc. The Company's product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis.

Other reports by

Discuss This Article